MedTrace Logo

A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.

NCT00708539 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2686

Last updated 2008-07-02

No results posted yet for this study

Summary

To compare the effect of Crinone 8% administered once daily versus other vaginal progesterone in terms of ongoing pregnancy rate 5 weeks after embryo transfer as well as patient convenience.

Conditions

  • IVF - Luteal Phase Support After Embryo Transfer

Interventions

DRUG

progesterone

90 mg, vaginal, once daily

DRUG

Progesterone

200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden

Sponsors & Collaborators

  • Merck Serono International SA

    collaborator INDUSTRY

  • Nordica Fertility Clinic

    lead OTHER

Principal Investigators

  • Svend Lindenberg · Nordica Fertilityclinic

  • Svend Lindenberg · Nordica Fertility Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708539 on ClinicalTrials.gov